3 April 2014 - Dabrafenib (Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the “Act on the Reform of the Market for Medicinal Products” (AMNOG), the German IQWiG had determined that dabrafenib has no added benefit in comparison with dacarbazine. IQWiG now assessed dabrafenib in comparison with vemurafenib. The report presented in the form of an addendum came to the same conclusion because the results from the indirect comparison presented by the drug manufacturer did not allow any reliable conclusions.

For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/dabrafenib_also_no_added_benefit_over_ve...